LS-1-2 demonstrated dose-dependent antiproliferative activity against KRAS-mutant CRC cell lines (IC50: 0.0819-0.9456 μM) and chemoresistant variants (HCT8-5-FU: 0.2239 μM; HCT116/self: 1.187 μM; PDC1: 0.1722 μM) (Figure 2B-C). The gene discussed is KRAS; the disease is colorectal carcinoma.